PRME Receives FDA RMAT Designation
Prime Medicine receives U.S. FDA Regenerative Medicine Advanced Therapy designation for PM359 to treat Chronic Granulomatous Disease
PRME - Prime Medicine Receives U.S.
FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)